演題抄録

ワークショップ

開催概要
開催回
第58回・2020年・京都
 

Pertuzumab、Trasutuzumab emtansine既治療のHER2陽性転移再発乳癌の検討

演題番号 : WS9-5

[筆頭演者]
奈良 美也子:1 
[共同演者]
足立 未央:1、熊木 裕一:1、岩本 奈織子:1、米倉 利香:1、石場 俊之:1、本田 弥生:1、宮本 博美:1、有賀 智之:1

1:がん・感染症センター都立駒込病院・外科(乳腺)

 

Introduction: Pertuzumab (PER) and Trasutuzumab Emtansine (T-DM1) are the standard treatment of HER2-positive metastatic breast cancer (HER2-MBC). But there was few data about clinical outcome after T-DM1 and make it difficult to establish recommended treatment. So we examined cases which received T-DM1 after PER and who changed next treatment due to progressive disease to reveal what kind of factors predicts destiny after T-DM-1 treatment.
Methods: From September 2013 to April 2020, Twenty-two HER2-MBC cases were included. We evaluated age, subtype, metastatic site, duration of T-DM1, progression free survival (PFS) and clinical benefit rate (CBR) of treatment immediately after T-DM1, overall survival (OS) and outcome.
Results: The median age was 54.5 years (range 36-74), 10 cases were ER-positive. HER2 status was confirmed by IHC in 20 cases and ISH in two cases (both IHC 2+ cases). There were 14 cases of visceral metastases and 4 cases of brain metastases. The median duration of T-DM1 was 7.1 months(M). The median PFS of treatment immediately after T-DM1 was 6M (range 1-58), and the CBR was 41%. At the time of data cut off, 11 cases were alive and 11 cases were dead. Differentiated PFS into two groups by median value, brain metastases cases had significantly shorter PFS (P=0.04) by the chi-square test. But there was no significant difference in OS by the Kaplan-Meier method(P=0.21).
Conclusion: In our study, the median PFS of treatment immediately after T-DM1 was 6M ,and the CBR was 41%. Especially, patients with brain metastases were likely to develop PD early without responding to treatment after T-DM1. From the results of DESTINY-BREAST01, The median PFS and CBR of Trasutuzumab Deruxtecan were reported to be 16.4M and 76.1%. These are the data for patients treated after T-DM1. So,"Trasutuzumab Deruxtecan enheartens to change the destiny."

キーワード

臓器別:乳腺

手法別:分子標的治療

前へ戻る